SPY314.38-1.80 -0.57%
DIA257.24-3.48 -1.33%
IXIC10,547.75+55.25 0.53%

AC Immune Reports Shareholders Approved All Resolutions For Annual Shareholder Meeting; Chair Highlights Expectation For Topline Data For Phase 2 Trial Of Anti-Tau Antibody Semorinemab In Alzheimer's In H2'20

Benzinga · -